-
2 months ago | 
jamanetwork.com | Nathan Watson |Jason H. Wasfy |Christopher Baugh |James L. Januzzi
Cardiac Biomarker Testing in US Emergency Departments Patient characteristics and presenting symptoms are used in risk stratification for individuals evaluated in the emergency department (ED) as to their likelihood of having acute coronary syndrome (ACS). Identifying those at risk of ACS can inform selective cardiac biomarker testing.
-
Oct 16, 2024 | 
jamanetwork.com | Siddhartha Mengi |Quebec Heart |Quebec City |James L. Januzzi
Aortic Stenosis, Heart Failure, and Aortic Valve Replacement
Abstract
Importance
Heart failure (HF) and aortic stenosis (AS) frequently coexist, presenting a complex clinical challenge due to their intertwined pathophysiology and associated high morbidity and mortality.
-
Jun 27, 2024 | 
healio.com | Scott Buzby |James L. Januzzi |Richard Smith
You've successfully added to your alerts. You will receive an email when new content is published. Click Here to Manage Email Alerts We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected]. Key takeaways:Due to overreliance on high-sensitivity biomarkers alone, misdiagnosis and overdiagnosis of heart attack have increased. Consequences include downstream testing, insurability effects and financial burden.
-
May 6, 2024 | 
jacc.org | J. Sawalla Guseh |James L. Januzzi
References1. "Association between playing American football in the National Football League and long-term mortality". JAMA . 2018;319:800-806. https://doi.org/10.1001/jama.2018.0140. 2. "NIOSH mortality study of NFL football players: 1959–1988". Cincinnati, OH: Centers for Disease Control and Prevention, National Institute of Occupational Safety and Health, 1994. 85-88. 3. "Body mass index, playing position, race, and the cardiovascular mortality of retired professional football players". Am J Cardiol .
-
Apr 24, 2024 | 
jamanetwork.com | Cian P. McCarthy |Jason H. Wasfy |James L. Januzzi
More than 750 000 individuals receive a diagnosis of myocardial infarction (MI) each year in the United States. This large number represents a small numerator compared with the massive denominator of the total number of individuals evaluated for the diagnosis. An enormous number of individuals are evaluated for MI because its underdiagnosis has become a major concern for clinicians.
-
Apr 8, 2024 | 
jacc.org | James L. Januzzi |Javed Butler |Stefano Del Prato |Justin A. Ezekowitz
References1. "Heart failure: an underappreciated complication of diabetes. A consensus report of the American Diabetes Association". Diabetes Care . 2022;45:7: 1670-1690. 2. "High prevalence of previously unknown heart failure and left ventricular dysfunction in patients with type 2 diabetes". Diabetologia . 2012;55:8: 2154-2162. 3.
-
Apr 8, 2024 | 
uscjournal.com | David Austin |Harriette Van Spall |James L. Januzzi |Yugo Yamashita
ACC.24 — We are joined onsite by Dr David Austin (South Tees Hospitals NHS Foundation Trust, UK) to discuss the findings from the PROACT trial (NCT03265574). Anthracyclines used in the treatment of breast cancer cause damage to the muscle cells in the heart, resulting in cardiotoxicityPROACT is a phase III randomised superiority trial of enalapril for the prevention of anthracycline-induced cardiotoxicity in patients treated for breast cancer and lymphoma.
-
Apr 8, 2024 | 
uscjournal.com | Harriette Van Spall |James L. Januzzi |Mikhail Kosiborod |Gregg Stone
ACC 2024 — Late-breaker host Dr. Harriette Van Spall (McMaster University, CA) sits down with Dr. James L. Januzzi (Massachusetts General Hospital & Harvard Medical School, US) to discuss the latest findings from the Aldose Reductase Inhibition for Stabilization of Exercise Capacity in Heart Failure trial (ARISE-HF, Applied Therapeutics, Inc) (NCT04083339).
-
Apr 8, 2024 | 
uscjournal.com | Rasha Al-Lamee |Michael Anne Foley |Harriette Van Spall |James L. Januzzi
ACC.24 — Investigators, Dr Rasha K Al-Lamee and Dr Michael Foley (Imperial College London, UK) joined us to discuss the ORBITA COSMIC trial (NCT04892537). This randomized, double-blinded, placebo-controlled trial investigated the effects of coronary sinus reducer (CSR) as compared to placebo on myocardial perfusion via MRI, exercise duration, and symptoms in patients with refractory angina and ischemia.
-
Apr 1, 2024 | 
healio.com | Scott Buzby |Richard Smith |Zachary Cox |James L. Januzzi
You've successfully added to your alerts. You will receive an email when new content is published. Click Here to Manage Email Alerts We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected]. Key takeaways: Dapagliflozin did not improve diuretic efficiency for patients hospitalized with acute HF. It did, however, require fewer diuretic doses, fewer daily uptitrations and shorter hospital stay vs. usual care.
